1-3 of 3
Ｍasashi Wakabayashi
Close
Sort by
Journal Articles

Final Analysis of JCOG0203 for Advanced-Stage Indolent B-Cell Lymphoma 15 Years after the End of Enrollment: Pooled Analysis of Arms a and B for Follicular Lymphoma

Takashi Watanabe, Kensei Tobinai, Ｍasashi Wakabayashi, Dai Maruyama, Kazuhito Yamamoto, Nobuko Kubota, Kazuyuki Shimada, Kohsuke Asagoe, Motoko Yamaguchi, Kiyoshi Ando, Michinori Ogura, Junya Kuroda, Youko Suehiro, Yoshihiro Matsuno, Kunihiro Tsukasaki, Hirokazu Nagai
Journal: Blood
Blood (2022) 140 (Supplement 1): 3615–3617.
https://doi.org/10.1182/blood-2022-159967
Published: 2022
Journal Articles

Ten-Year Follow-up of Newly Diagnosed Follicular Lymphoma Patients Treated with Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) As First-Line Therapy in JCOG0203 Trial

Takashi Watanabe, MDPhD, Kensei Tobinai, MD, PhD, Masashi Wakabayashi, MSc, Yasuo Morishima, MDPhD, Hirobumi Kobayashi, MD PhD, Tomohiro Kinoshita, MD PhD, Takayo Suzuki, MD PhD, Motoko Yamaguchi, MDPhD, Kiyoshi Ando, MD PhD, Michinori Ogura, MD PhD, Masafumi Taniwaki, MD PhD, Naokuni Uike, MD, PhD, Tadashi Yoshino, MD PhD, Shigeru Nawano, MD PhD, Takashi Terauchi, MD PhD, Tomomitsu Hotta, MD PhD, Kunihiro Tsukasaki, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 5168.
https://doi.org/10.1182/blood.V130.Suppl_1.5168.5168
Published: 2017
Journal Articles

The Response Evaluation Criteria in Solid Tumors Can be Substituted for the International Workshop Criteria?: Comparison Using Japan Clinical Oncology Group Study JCOG0203 for Untreated Indolent B-Cell Lymphoma

Kenichi Miyamoto, MD, Takashi Watanabe, MD PhD, Hideaki Kitahara, MD, Masashi Wakabayashi, MSc, Kenichi Nakamura, MD, Yuko Watanabe, Dai Maruyama, MD PhD, Kensei Tobinai, MD, PhD, Kunihiro Tsukasaki, MD, Haruhiko Fukuda, MD
Journal: Blood
Blood (2016) 128 (22): 4779.
https://doi.org/10.1182/blood.V128.22.4779.4779
Published: 2016